Sonnet Delays Merger Vote, Targeting a $1 Billion Digital Asset Venture

Sonnet BioTherapeutics has announced a delay in its merger vote with Hyperliquid Strategies Inc. and Rorschach I LLC to December 2025. This move seeks to secure majority shareholder approval before finalizing the merger that aims to create a $1 billion digital asset treasury. Initial projections show over 95% of shareholders supporting this merger, though it hasn’t yet reached quorum requirements for finalization.